

RECEIVED

APR 24 2001

TECH CENTER 2000/2900
CU-2140 TJK

GAV 1643

#7

THE UNITED STATES PATENT AND TRADEMARKS OFFICE

In re Application of: Raa et al.

) NOVEL, NON-ANTIGENIC,
) MUCOSAL ADJUVANT
) FORMULATION WHICH
) MODULATES THE
) EFFECTS OF SUBSTANCES,
) INCLUDING VACCINE
) ANTIGENS, IN CONTACT
) WITH MUCOSAL BODY
) SURFACES
)
) Group Art Unit: 1643
) Examiner: J Stucker

Serial No.: 09/511,582

Filed: February 23, 2000

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed the following in the above referenced patent application:

1. Executed Revocation of Power, Power of Attorney and Notice of Change of Correspondence Address.

Please acknowledge receipt of the above by returning the enclosed stamped, self-addressed receipt postcard.


Please charge any additional fees to Deposit Account No. 23-2126. A duplicate of this transmittal is enclosed.

Date: 4/17/01

Wildman, Harrold, Allen & Dixon
0225 West Wacker Drive
Chicago, IL 60606
Ph. (312) 201-2000
Fax (312) 201-2555

Respectfully submitted,

By:


Timothy J. Keefer, Reg. No. 35,567

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for patents, Washington, D.C. 20231 on

4/17/01

Munday, Stucke

AUTHORISATION

The board of Biotec ASA hereby authorise each Mr. Gunnar Rørstad and Ms. Kirsti Nikolaisen to sign and act on behalf of the company in patent and trademark issues relating to the group's business, including, but not limited to, patents and trademark applications.

This authorisation is valid as from 6 October 2000, and until it is withdrawn in writing.

Oslo, 6 October 2000



Stein Holst Annexstad
Chairman



Jan Raa
Boardmember